lung cancer
Conditions
Interventions
experimental group: carrelizumab combined with platinum-containing dual-drug chemotherapy
Sponsors
Affiliated Hospital of Xuzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years, no gender limit; 2. Stage II-IIIA resectable squamous non-small cell lung cancer diagnosed by histopathology or cytology; 3. EGFR / ALK and other driver genes are negative; 4. Squamous non-small cell lung cancer has not received any treatment in the past; 5. The subject must have sufficient lung function to tolerate lung resection; 6. According to the RECIST 1.1 standard, the subject must have a measurable target lesion that can be examined by CT or MRI; 7. The World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) physical performance score (PS) was 0 or 1 when the patient was enrolled; 8. Life expectancy >= 3 months; 9. The patient signs an informed consent form and voluntarily joins the study; 10. There is no serious liver and kidney function damage, and the function level of the organs must meet the following requirements: ANC >= 1.5x10^9/L; PLT >= 90x10^9/L; Hb >= 90 g/L; TBIL = 50 mL/min (Cockcroft-Gault formula); LVEF >= 50%; QT interval adjusted by Fridericia method (QTcF) Male <450 ms, female <470 ms; INR <= 1.5xULN, ACTT <= 1.5xULN.
Exclusion criteria
Exclusion criteria: 1. Patients with allergies or hypersensitivity to treatment drugs, patients with autoimmune diseases; 2. There is fluid in the third space that cannot be controlled by drainage or other methods (such as large amounts of pleural fluid and ascites); 3. Use steroids for more than 50 days, or need to use steroids for a long time; 4. Uncontrolled symptomatic brain metastases or mental disorders that cannot correctly express subjective symptoms; 5. Receive any other anti-tumor treatments at the same time, including anti-tumor Chinese patent medicines and immune preparations; 6. Other malignant tumors occurred within 5 years before enrollment, except for cervical carcinoma in situ or skin squamous or basal cell carcinoma that was previously treated for the purpose of radical treatment; 7. Women who are pregnant or breastfeeding, have fertility but refuse to take contraceptive measures; 8. Have received allogeneic tissue/solid organ transplantation; 9. According to the judgment of the investigator, there are accompanying diseases that seriously endanger the safety of the patient or affect the completion of the study (such as uncontrolled hypertension, diabetes, thyroid disease, etc.); 10. The investigator judges other situations that are not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main pathological remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Pathological complete remission rate;Adverse events; | — |
Countries
china
Contacts
Public ContactLuo Tao
Affiliated Hospital of Xuzhou Medical University
Outcome results
None listed